Adani and executives face expanded U.S. indictment alleging a $250 million bribery scheme to Indian officials for solar power contracts, leading to significant financial and political repercussions.
Novartis raises mid-term sales guidance, citing strong drug performance and promising pipeline, but analysts express concerns about sustaining growth beyond 2029.
Adani and executives face expanded U.S. indictment alleging a $250 million bribery scheme to Indian officials for solar power contracts, leading to significant financial and political repercussions.
Novartis raises mid-term sales guidance, citing strong drug performance and promising pipeline, but analysts express concerns about sustaining growth beyond 2029.